Thale Jarvis of Crestone joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘novel drug discovery programs for emerging infectious diseases’.
In this presentation, learn about CRS3123 for the treatment of Clostridium difficile infections.
Download the presentation to understand more about:
- Crestone’s mission
- Clostridium difficile infection (CDI)
- CRS3123: Key advantages vs. competition
…and much more!
Get your copy here!
To find out more about how CRS3123 is competing in the gram positive market , attend World Anti-Microbial Resistance Congress USA 2016 held September 8-9 in Washington, DC .